Section Arrow
ATYR.NASDAQ
- aTyr Pharma Inc
(Financial Status)
Quotes are at least 15-min delayed:2026/02/23 16:38 EST
After Hours
Last
 0.9908
-0.0192 (-1.90%)
Bid
0.9907
Ask
1.05
High 1.03 
Low 0.9907 
Volume 10.77K 
Regular Hours (Closed)
Last
 1.01
-0.03 (-2.88%)
Day High 
1.1 
Prev. Close
1.04 
1-M High
1.11 
Volume 
2.51K 
Bid
0.9907
Ask
1.05
Day Low
0.9901 
Open
1.05 
1-M Low
0.6701 
Market Cap 
101.91M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.95 
20-SMA 0.88 
50-SMA 0.79 
52-W High 7.2904 
52-W Low 0.64 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.83/-0.77
Enterprise Value
113.94M
Balance Sheet
Book Value Per Share
0.82
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
235.00K
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GOSSGossamer Bio0.42055-1.70945-80.26%-- 
After Hours 0.3935 -0.02705 -6.43%
ELABPMGC Holdings Inc.1.21-0.08-6.20%0.01PE
After Hours 1.2102 +0.0002 +0.02%
IBRXImmunityBio9.82+1.12+12.87%-- 
After Hours 9.76 -0.06 -0.61%
VNDAVanda Pharmaceuticals8.17+2.41+41.84%-- 
After Hours 8.22 +0.05 +0.61%
IKTInhibikase Therapeutics1.8+0.04+2.27%3.74PE
After Hours 1.79 -0.01 -0.56%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause tofibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.